JP2024510526A5 - - Google Patents

Info

Publication number
JP2024510526A5
JP2024510526A5 JP2023559011A JP2023559011A JP2024510526A5 JP 2024510526 A5 JP2024510526 A5 JP 2024510526A5 JP 2023559011 A JP2023559011 A JP 2023559011A JP 2023559011 A JP2023559011 A JP 2023559011A JP 2024510526 A5 JP2024510526 A5 JP 2024510526A5
Authority
JP
Japan
Prior art keywords
cysteine
domain
positions
antibody construct
cysteine residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050453 external-priority patent/WO2022198335A1/en
Publication of JP2024510526A publication Critical patent/JP2024510526A/ja
Publication of JP2024510526A5 publication Critical patent/JP2024510526A5/ja
Pending legal-status Critical Current

Links

JP2023559011A 2021-03-26 2022-03-25 システイン操作された抗体コンストラクト、コンジュゲート、及び使用方法 Pending JP2024510526A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166450P 2021-03-26 2021-03-26
US63/166,450 2021-03-26
PCT/CA2022/050453 WO2022198335A1 (en) 2021-03-26 2022-03-25 Cysteine engineered antibody constructs, conjugates and methods of use

Publications (2)

Publication Number Publication Date
JP2024510526A JP2024510526A (ja) 2024-03-07
JP2024510526A5 true JP2024510526A5 (cg-RX-API-DMAC7.html) 2025-04-03

Family

ID=83395224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559011A Pending JP2024510526A (ja) 2021-03-26 2022-03-25 システイン操作された抗体コンストラクト、コンジュゲート、及び使用方法

Country Status (11)

Country Link
US (1) US20260042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314043A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024510526A (cg-RX-API-DMAC7.html)
KR (1) KR20230171944A (cg-RX-API-DMAC7.html)
CN (1) CN117242091A (cg-RX-API-DMAC7.html)
AU (1) AU2022243931A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019698A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178093A1 (cg-RX-API-DMAC7.html)
IL (1) IL307231A (cg-RX-API-DMAC7.html)
MX (1) MX2023011316A (cg-RX-API-DMAC7.html)
WO (1) WO2022198335A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023350792A1 (en) * 2022-09-28 2025-03-27 Zymeworks Bc Inc. Antibody drug conjugates targeting c-met and methods of use
KR20260005971A (ko) * 2023-04-29 2026-01-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 변형된 항체, 이의 항체 단편, 및 항체-약물 접합체
EP4548936A1 (en) 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
EP4706676A1 (en) * 2024-09-10 2026-03-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cysteine-engineered antigen-binding domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2719584T3 (es) * 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3525826B1 (en) * 2016-10-11 2020-07-22 Byondis B.V Non-linear self-immolative linkers and conjugates thereof
CN108743968B (zh) * 2017-06-20 2022-04-19 成都百利多特生物药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选
CN111434687B (zh) * 2019-01-15 2022-03-11 南京赛新生物科技有限公司 一种抗体及其应用
AU2021225962A1 (en) * 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation

Similar Documents

Publication Publication Date Title
JP7467610B2 (ja) カンプトテシン誘導体及びその複合体
JP7817236B2 (ja) 抗cd79b抗体薬物複合体、その調製方法及びその医薬用途
JP7730836B2 (ja) 抗体薬物複合体の調製方法
KR102962848B1 (ko) 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도
JP7323513B2 (ja) 抗4-1bb抗体とその作製及び使用方法
TW202203978A (zh) 電荷可變連接子
JP2022530089A5 (cg-RX-API-DMAC7.html)
CN111148761A (zh) 多特异性抗体及其制备和使用方法
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2006506955A5 (cg-RX-API-DMAC7.html)
JP2018500014A (ja) B細胞成熟化抗原を標的化する抗体および使用の方法
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2023516004A5 (cg-RX-API-DMAC7.html)
CN110831973A (zh) 多特异性抗体及其制备和使用方法
CN117946278A (zh) 多特异性抗体及其制备和使用方法
JP2024119853A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
CA3205707A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
JP2021515793A5 (cg-RX-API-DMAC7.html)
JP2011516041A5 (cg-RX-API-DMAC7.html)
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2023552733A (ja) 抗クローディン-18.2抗体及びその抗体薬物複合体
JP2008515889A5 (cg-RX-API-DMAC7.html)
JP2023547506A5 (cg-RX-API-DMAC7.html)
JP2023516941A5 (cg-RX-API-DMAC7.html)